![conference banner](/images/conference-banner.jpeg)
Abstract
Several lines of evidence indicate that the etiology of late-onset Alzheimer’s disease (LOAD) is complex, with significant contributions from both genes and environmental factors. Recent research suggests the importance of epigenetic mechanisms in defining the relationship between environmental exposures and LOAD. In epidemiologic studies of adults, cumulative lifetime lead (Pb) exposure has been associated with accelerated declines in cognition. In addition, research in animal models suggests a causal association between Pb exposure during early life, epigenetics, and LOAD. There are multiple challenges to human epidemiologic research evaluating the relationship between epigenetics, LOAD, and Pb exposure. Epidemiologic studies are not well-suited to accommodate the long latency period between exposures during early life and onset of Alzheimer’s disease. There is also a lack of validated circulating epigenetics biomarkers and retrospective biomarkers of Pb exposure. Members of our research group have shown bone Pb is an accurate measurement of historical Pb exposure in adults, offering an avenue for future epidemiologic studies. However, this would not address the risk of LOAD attributable to early-life Pb exposures. Future studies that use a cohort design to measure both Pb exposure and validated epigenetic biomarkers of LOAD will be useful to clarify this important relationship.
Keywords: DNA methylation; epigenetics; epidemiology, Late-onset Alzheimer’s disease; lead exposure, Pb.
Current Alzheimer Research
Title:Alzheimer’s Disease and Environmental Exposure to Lead: The Epidemiologic Evidence and Potential Role of Epigenetics
Volume: 9 Issue: 5
Author(s): Kelly M. Bakulski, Laura S. Rozek, Dana C. Dolinoy, Henry L. Paulson and Howard Hu
Affiliation:
Keywords: DNA methylation; epigenetics; epidemiology, Late-onset Alzheimer’s disease; lead exposure, Pb.
Abstract: Several lines of evidence indicate that the etiology of late-onset Alzheimer’s disease (LOAD) is complex, with significant contributions from both genes and environmental factors. Recent research suggests the importance of epigenetic mechanisms in defining the relationship between environmental exposures and LOAD. In epidemiologic studies of adults, cumulative lifetime lead (Pb) exposure has been associated with accelerated declines in cognition. In addition, research in animal models suggests a causal association between Pb exposure during early life, epigenetics, and LOAD. There are multiple challenges to human epidemiologic research evaluating the relationship between epigenetics, LOAD, and Pb exposure. Epidemiologic studies are not well-suited to accommodate the long latency period between exposures during early life and onset of Alzheimer’s disease. There is also a lack of validated circulating epigenetics biomarkers and retrospective biomarkers of Pb exposure. Members of our research group have shown bone Pb is an accurate measurement of historical Pb exposure in adults, offering an avenue for future epidemiologic studies. However, this would not address the risk of LOAD attributable to early-life Pb exposures. Future studies that use a cohort design to measure both Pb exposure and validated epigenetic biomarkers of LOAD will be useful to clarify this important relationship.
Export Options
About this article
Cite this article as:
M. Bakulski Kelly, S. Rozek Laura, C. Dolinoy Dana, L. Paulson Henry and Hu Howard, Alzheimer’s Disease and Environmental Exposure to Lead: The Epidemiologic Evidence and Potential Role of Epigenetics, Current Alzheimer Research 2012; 9 (5) . https://dx.doi.org/10.2174/156720512800617991
DOI https://dx.doi.org/10.2174/156720512800617991 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chromogranins and Inositol 1,4,5-Trisphosphate-Dependent Ca2+-Signaling in Cardiomyopathy and Heart Failure
Current Medicinal Chemistry Application of Cardiac Molecular Imaging Using Positron Emission Tomography in Evaluation of Drug and Therapeutics for Cardiovascular Disorders
Current Pharmaceutical Design Is Elevated Norepinephrine an Etiological Factor in Some Cases of Alzheimers Disease?
Current Alzheimer Research Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?
Current Pharmaceutical Design Non-cholesterol Sterols in the Diagnosis and Treatment of Dyslipidemias: A Review
Current Medicinal Chemistry Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives
Current Stem Cell Research & Therapy Cannabinoid Modulation of Neuroinflammatory Disorders
Current Neuropharmacology Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology Substance-Related Disorders and Somatic Symptoms: How Should Clinicians Understand the Associations?
Current Drug Abuse Reviews Low Lymphocyte Count and Cardiovascular Diseases
Current Medicinal Chemistry Peptide Therapeutics in Neurodegenerative Disorders
Current Medicinal Chemistry Developing Practical Therapeutic Strategies that Target Protein SUMOylation
Current Drug Targets Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry 3, 5-Diiodothyronine: Biological Actions and Therapeutic Perspectives
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of Adenosine in Alzheimers Disease
Current Neuropharmacology Xenobots: Applications in Drug Discovery
Current Pharmaceutical Biotechnology Endothelin and Subarachnoid Hemorrhage-Induced Cerebral Vasospasm: Pathogenesis and Treatment
Current Medicinal Chemistry Sex Steroid Hormones, Cardiovascular Diseases and The Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Mitochondrial Serine Protease HtrA2/Omi as a Potential Therapeutic Target
Current Drug Targets Adipose-Renal Axis in Diabetic Nephropathy
Current Medicinal Chemistry